The FDA’s recent back-and-forth regarding Moderna’s mRNA flu vaccine application has injected a dose of uncertainty into the biopharmaceutical industry. Just one week after initially refusing to review the application, the agency announced on February 18, 2026, that it will now proceed with a review of the vaccine for adults aged 50, and older. This reversal comes after Moderna proposed a revised regulatory pathway, seeking full approval for those aged 50-64 and accelerated approval—with a requirement for further study—for those 65 and older. The evolving situation highlights the complexities of navigating the regulatory landscape for novel vaccines, particularly as the agency operates under new leadership and shifting priorities.
The initial rejection stemmed from concerns about the design of Moderna’s Phase 3 clinical trial. The FDA’s Center for Biologics Evaluation and Research (CBER) deemed the study “not adequate and well-controlled,” specifically questioning the use of a standard-dose flu shot as a comparator for adults 65 and older. Regulators indicated a preference for a high-dose flu vaccine in that age group, reflecting the best-available standard of care. Moderna maintained that the study design had previously been approved by CBER, and that the agency had not raised concerns about the vaccine’s safety or efficacy. The company’s CEO, Stéphane Bancel, expressed confusion over the initial decision, stating the FDA had not previously voiced these concerns.
A Shift in Regulatory Strategy
To address the FDA’s concerns, Moderna proposed splitting its application into two parts. The company is now seeking traditional FDA approval for the vaccine in adults aged 50 to 64, and accelerated approval for those 65 and older. Accelerated approval will be contingent on a post-marketing study to gather additional data in the older age group. The FDA accepted this revised approach, setting a review deadline of August 5, 2026. “We appreciate the FDA’s engagement in a constructive Type A meeting and its agreement to advance our application for review,” Bancel said in a news release. “Pending FDA approval, we look forward to making our flu vaccine available later this year so that America’s seniors have access to a new option to protect themselves against flu.”
Broader Context: mRNA Vaccine Scrutiny
This regulatory saga unfolds against a backdrop of shifting federal policy regarding mRNA vaccine technology. Since August 2025, the Department of Health and Human Services (HHS), under the leadership of Secretary Robert F. Kennedy Jr., has slashed $500 million in mRNA contracts. Kennedy has long been a vocal opponent of mRNA vaccines, including those developed during Operation Warp Speed to combat COVID-19. This reduction in funding, coupled with the initial rejection of Moderna’s flu vaccine application, sent ripples through the vaccine market, prompting some manufacturers to cut jobs and scale back research efforts in the United States, according to reporting from The New York Times.
Expert Reactions and Concerns
The FDA’s initial refusal and subsequent reversal have left some experts baffled. “We don’t have any idea why they reversed course,” said Michael Osterholm, PhD, MPH, director of the University of Minnesota’s Center for Infectious Disease Research and Policy, which publishes CIDRAP News. “That’s part of the problem.” Osterholm emphasized the need for consistent policy and clear approval pathways for vaccine developers. “They need to know what is needed for approval, and how it would be supported after approval. Without that we will see a rapidly changing vaccine landscape.” He added, “This current situation demonstrates how out of control we are in the FDA’s consideration and review of currently licensed vaccines and potential new vaccines.”
Robert H. Hopkins Jr., MD, medical director of the National Foundation for Infectious Diseases, expressed cautious optimism about the FDA’s decision to review the application. “It’s hard to assess whether this is an indication of changes in agency leadership’s approach to new vaccine applications or not; but I am hopeful that it does,” Hopkins said in a statement. He highlighted the potential benefits of a rapidly adaptable mRNA vaccine platform for addressing evolving influenza strains, stating that it “will potentially be a major step forward in efforts to protect the health of individuals from severe influenza.”
What’s Next for Moderna’s Flu Vaccine?
With the FDA now reviewing the application, the focus shifts to the agency’s assessment of the data and its decision regarding approval. The August 5, 2026 deadline sets a clear timeline for this process. The FDA’s decision will not only impact Moderna but also shape the future of mRNA vaccine development and the broader influenza prevention landscape. The agency’s review will likely scrutinize the efficacy and safety data, particularly in the 65+ age group, and assess the need for the post-marketing study proposed by Moderna. The outcome will be closely watched by public health officials, vaccine manufacturers, and individuals seeking effective protection against the flu.
The approval of a new flu vaccine, particularly one utilizing mRNA technology, could offer a significant advantage in combating seasonal influenza. MRNA vaccines offer the potential for faster development and adaptation to emerging viral strains compared to traditional egg-based vaccines. This flexibility could be crucial in addressing the ongoing challenge of influenza’s antigenic drift and shift.
This is a developing story. Readers can find updates on the FDA’s website and through Moderna’s investor relations page.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What do you think about the FDA’s decision? Share your thoughts in the comments below, and please share this article with your network.
